← All Signals

🏥 FDA: McKesson — Class I

healthcarebearishSource: FDA
85%Confidence
0Views
FDASource
2026-03-07Date

Summary

McKesson faces a Class I recall for UDENYCA due to temperature abuse, indicating potential product efficacy issues that could impact patient outcomes and regulatory scrutiny. This recall may affect McKesson's distribution reputation and Accord BioPharma's manufacturing credibility, potentially leading to supply chain disruptions for pegfilgrastim products.

Actionable: Monitor McKesson's stock for potential short-term volatility and assess alternative suppliers for pegfilgrastim products.

AI Confidence: 85%

Data Points

firmMcKesson
classificationClass I
statusOngoing
distributionNationwide in the USA
productUDENYCA, pegfilgrastim-cbqv injection, 6 mg/0.6mL Single Dose Prefilled Syringe, Rx only, Manufactured by Accord BioPharma, Inc., 8041 Arco Corporate

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now